GNLX: מכפיל P/S עתידי Genelux Corp

The forward P/S dynamics demonstrate the long-term valuation trend of Genelux Corporation (GNLX), where 8720.40 becomes the new value for this metric. Genelux Corporation (GNLX) creates viral platforms to combat solid tumors by activating the patient's immunity. The innovative Olvi-Vec ecosystem provides patent protection and connectivity with medical centers. The business is currently actively developing a line of drugs for selective cancer immunotherapy.
פילוחי נתונים אנליטיים מרוכזים עבור Genelux Corp. (GNLX)

Bioprocess automation at Genelux Corporation (GNLX) minimizes operational risks, which directly impacts expected revenue and shapes the projected P/S valuation. This indicator compares current market capitalization with future earnings, allowing investors to determine whether the price includes a premium for technological leadership or if the asset has become overvalued, thereby reducing the business's margin of safety.